AKT1 and ovarian carcinoma: Indeed, published data highlighted that tissue samples from patients who had undergone surgery for endometriosis-associated ovarian cancers or endometriotic ovarian cysts show loss of BAF250a expression in 22% endometrioid cancers, 47% of clear cell cases, 44% of contiguous endometriosis cases, and 8% of benign endometriotic ovarian cysts; in addition, the expression of phosphorylated AKT, γH2AX, BIM, and BAX was higher in endometriosis-associated ovarian cancers and contiguous endometriosis than in benign endometriosis, whereas expression of pATM, pCHK2, and Bcl2 was low [342].